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Abstract: Advances in the clinical assessment strategies used to identify neonates at risk for the 
development of severe hyperbilirubinemia and bilirubin neurotoxicity, as well as the treatment 
measures to control hyperbilirubinemia in newborns, continue to be made. They include, among 
others, universal predischarge birth hospitalization bilirubin screening, the confirmation that 
hemolysis is an important risk factor for bilirubin neurotoxicity, the use of a numeric scoring 
system to help stage the severity of acute bilirubin encephalopathy, the potential advantages of 
turquoise-light phototherapy, and the potential role of heme-oxygenase inhibitors in preventing 
the need for exchange transfusions, all of which are reviewed here.
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Introduction
Neonatal hyperbilirubinemia is the most common clinical condition in the 
  newborn requiring evaluation and management and remains a frequent reason for 
hospital readmission during the first week of postnatal life.1,2 The high prevalence 
of neonatal hyperbilirubinemia reflects developmental red blood cell, hepatic, and 
gastrointestinal immaturities that result in an imbalance favoring bilirubin production 
over hepatic–enteric bilirubin clearance.3,4 For most neonates, hyperbilirubinemia is a 
benign postnatal transitional phenomenon of no overt clinical effect. A subset of infants, 
however, will develop more significant hyperbilirubinemia. The estimated occurrence 
of hyperbilirubinemia based on peak total serum bilirubin (TSB) severity has been 
reported as: more than 17 mg/dL (291 µmol/L), defined as significant, at ∼1 in 10; 
more than 20 mg/dL (342 µmol/L), defined as severe, at ∼1:70; more than 25 mg/dL 
(428 µmol/L), defined as extreme, at ∼1:700; and more than 30 mg/dL (513 µmol/L), 
defined as hazardous, at ∼1:10,000 live births.5,6
Marked hyperbilirubinemia can lead to acute bilirubin encephalopathy (ABE) 
and evolve into chronic bilirubin encephalopathy (CBE), a devastating, permanently 
disabling neurologic disorder7–10 synonymous with kernicterus.11 The central nervous 
system sequelae of kernicterus reflect both a predilection of bilirubin toxicity for 
neurons (relative to glial cells) and the regional topography of bilirubin-induced 
neuronal damage characterized by prominent involvement of the globus pallidus and 
subthalamic nuclei, the eighth cranial nerve and cochlear nuclei, the dorsal midbrain 
periaqueductal grey, and the dentate nuclei of the cerebellum.7,10,12,13 CBE is classically 
characterized by dystonia, athetosis, auditory neuropathy spectrum disorder, paresis of Research and Reports in Neonatology 2014:4 submit your manuscript | www.dovepress.com
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vertical gaze, and dental enamel dysplasia.7,10 The prevention 
of kernicterus remains a serious clinical concern for neonatal 
caregivers worldwide.9,14,15
Despite the implementation of evaluation and treat-
ment guidelines for neonatal hyperbilirubinemia by the 
American Academy of Pediatrics (AAP)11,16 and others 
to “reduce the incidence of severe hyperbilirubinemia 
and bilirubin encephalopathy,” cases of kernicterus are 
still occurring in the United States, Canada, Europe, and 
elsewhere.17 In developed countries, population-based 
estimates for kernicterus in term infants range from 1 in 
30,000 to 1 in 200,000 live births.17
The current review focuses on recent advances in our 
approach to risk assessment for the development of severe 
hyperbilirubinemia and bilirubin neurotoxicity, as well 
as treatment measures to control hyperbilirubinemia in 
newborns. The crux of hyperbilirubinemia and bilirubin-
induced neurotoxicity risk evaluation remains the measure-
ment of total serum bilirubin interpreted in an hour-specific 
fashion,17,18 and the mainstays of intervention are photo-
therapy and exchange transfusion.19,20 These are detailed, 
along with other evaluation strategies, clinical tools, and 
adjunctive therapies, including several currently under 
study that hold promise for potential future application 
to the management of neonatal jaundice.
Universal predischarge birth 
hospitalization bilirubin screening
Experience with implementation of the 2004 AAP clinical 
practice guideline on the management of hyperbilirubinemia 
in the newborn at 35 or more weeks’ gestation coupled with 
several subsequent clinical studies led to a 2009 update with 
clarifications.16 The update was notable for recommending 
universal predischarge birth hospitalization bilirubin screen-
ing using TSB or transcutaneous (TcB) measurements to help 
assess the risk for subsequent severe hyperbilirubinemia.16 
The predischarge bilirubin measurement combined with the 
gestational age of the infant make up a particularly robust 
predictor of subsequent severe hyperbilirubinemia16,21–23 that 
is consistent with the importance of immaturity as a risk fac-
tor for jaundice (Figure 1).16,22 Studies consistently demon-
strate that implementation of routine predischarge bilirubin 
screening is associated with significantly reduced numbers 
of infants with extreme or hazardous hyperbilirubinemia,24–26 
most recently showing a decrease from 11.5 cases of haz-
ardous bilirubin (TSB $30 mg/dL) per 100,000 live births 
before universal bilirubin screening to 4.3 per 100,000 after 
implementation of universal bilirubin screening in Kaiser 
Permanente Northern California facilities.26 TSB and TcB 
measurement interpreted in an hour-specific fashion is an 
integral part of currently applied clinical guidelines in the 
management of the jaundiced neonate.11,16
Some brief comments on TcB are warranted. Strictly 
speaking, TcB is a measure of the yellow color of blanched 
skin and subcutaneous tissue, not the serum, and only an 
indirect proxy of TSB.16 As such, TcB is a screening tool to 
help determine whether a TSB should be measured.16 TcB 
accuracy is best at lower TSB levels, and in general, the 
TcB tends to underestimate TSB, particularly at higher TSB 
concentrations.16,27 Thus, it is important to adopt approaches 
to avoid missing a high TSB when using TcB to screen for 
hyperbilirubinemia; for example, obtaining a TSB whenever 
the TcB reading is higher than 13 mg/dL.16
Neurotoxicity risk factors
The major determinants of bilirubin neurotoxicity cur-
rently in clinical use are the TSB, the gestational age of 
the neonate, and the presence of neurotoxicity risk factors. 
The latter are clinical conditions that might increase the 
risk for brain damage in an infant with severe hyperbiliru-
binemia and, as outlined in the 2004 AAP clinical practice 
guideline, include isoimmune hemolytic disease, glucose-
6-phosphate dehydrogenase (G6PD) deficiency, asphyxia, 
sepsis, acidosis, and albumin levels lower than 3.0 g/dL.11 
Each condition is used along with the hour-specific TSB and 
gestational age in the calculus to determine phototherapy 
(Figure 2) and exchange transfusion treatment thresholds 
for newborns.11,16 As highlighted in the 2009 update and the 
2004 AAP guideline, these interventions are recommended 
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Figure 1 Gestational age impacts risk for severe hyperbilirubinemia.
Notes: Risk of developing a total serum bilirubin (TSB) level of 20 mg/dL (342 µmol/L) 
or higher as a function of gestational age and percentile of the first TSB measured 
at less than 48 hours on the Bhutani nomogram.22 Copyright © 2005 American 
Medical Association. All rights reserved. Reproduced from Newman TB, Liljestrand 
P, escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict 
hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med. 2005;159(2):113–119.22
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at lower TSB when any of the neurotoxicity risk factors are 
present.11,16
TSB and neurotoxicity risk
TSB is the measure of albumin-bound bilirubin, whereas 
the small circulating fraction not bound to albumin or other 
serum proteins is indexed by the unbound or “free” (Bf) 
bilirubin level.9,28,29 The latter is in dynamic equilibrium with 
the extravascular tissues, including the central nervous 
system, and provides a measure of the relative amount of 
bilirubin that will exit the vascular space at a given level 
of TSB.9,28,29 TSB alone is of limited value in predicting neu-
rologic impairment and kernicterus in hyperbilirubinemic 
newborns,9,28–32 a conclusion reaffirmed in recent clinical 
studies.33,34 Nevertheless, it is clear that marked elevations 
in TSB are associated with kernicterus risk,6,31,33,35,36 and TSB 
remains for all intents and purposes the only biochemical 
measurement of bilirubin widely available to clinicians.
There continues to be a keen interest in Bf, the bilirubin-
albumin (B/A) ratio as a proxy of Bf, and the Bf/TSB ratio 
as potential more reliable indices of neurotoxicity risk 
than the TSB.9,28,29 At this time, however, no commercial 
instrument is available to measure Bf, although a newly 
developed fluorescence sensor for quantifying Bf in plasma 
has been detailed37 and applied in research reports.38,39 
This novel methodology is less complex than the previ-
ously studied horseradish peroxidase method, requires 
only a small sample volume, and therefore holds promise 
for clinical application in the future.37–39 In the interim, 
the most frequently used proxy for Bf is the ratio of TSB 
(mg/dL) to serum albumin (g/dL), an index that correlates 
with measured circulating Bf.40 Use of the B/A ratio has 
been endorsed by the AAP in determining the need for 
exchange transfusion, albeit in conjunction with, but not 
in lieu of, the TSB.11
Evidence from the recent prospective randomized multi-
center Bilirubin Albumin Ratio Trial (BART) in The Nether-
lands, however, showed that the neurodevelopmental outcome 
of preterm infants treated according to the B/A ratio or TSB 
(whichever was exceeded first) was not superior to those 
treated according to the TSB threshold alone.41 Although this 
study may have been underpowered (only 30% of infants in 
the experimental group were treated on the basis of the B/A 
ratio, as opposed to TSB), it is also possible that B/A ratios 
selected for study lacked sensitivity and that a lower B/A 
ratio than those used for intervention in the BART might 
better index neurotoxicity risk. Indeed, preliminary data from 
Japan suggest that lower B/A ratios may be more sensitive 
to unbound bilirubin levels in the putative neurotoxic range, 
and to bilirubin-induced abnormalities on brainstem auditory 
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Figure 2 American academy of pediatrics phototherapy guidelines.
Notes: Guidelines for phototherapy in hospitalized infants $35 weeks’ gestation. Risk factors are isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase 
deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or an albumin level of less than 3.0 g/dL (if measured). Use total bilirubin. Do not subtract 
direct-reacting or conjugated bilirubin. Reproduced with permission from Pediatrics, 124, 1193–1198, Copyright © 2009 by the AAP.16
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evoked responses, particularly in preterm neonates.42 For 
example, in infants of less than 30 weeks’ gestational age, 
a B/A molar ratio of 0.40 (equivalent to B/A of 3.4 mg/g) 
was predictive of a Bf of more than 1 µg/dL and abnormal 
brainstem auditory evoked responses, with 100% sensitivity 
and 85% specificity.42 In contrast to these, Iskander et al were 
unable to show improved sensitivity in predicting ABE, CBE, 
and hearing loss risk using B/A as compared with TSB in a 
large cohort of infants with TSB levels higher than 25 mg/
dL in Cairo.35 In fact, only a B/A molar ratio of 1:1 or greater 
(B/A ratio of $8.6 mg/g) was revelatory of ABE risk.35 The 
nature of the differences across these studies merit clarifica-
tion to determine the potential utility of B/A as a proxy of 
Bf and a predictor of neurotoxicity risk.
Should Bf measurements become clinically available, it will 
be important to remember that Bf and TSB are not competing 
independent determinants of bilirubin toxicity but, rather, criti-
cally interrelated and interdependent factors in estimating risk, a 
point highlighted by Ahlfors et al in several publications.28,29,40,43 
TSB is needed to gauge the size of the bilirubin load, and Bf its 
distribution.29 Ahlfors et al therefore suggest that the Bf-to-TSB 
ratio may be the best risk predictor of all (Figure 3).29,43 It will 
be of interest to study this possibility in a larger cohort once Bf 
measurements are available in the clinical arena.
An alternative or complementary approach to Bf and the 
Bf/TSB ratio in predicting bilirubin-induced neurotoxicity is the 
bilirubin binding capacity (BBC), using hematofluorometry.44 
The latter index provides a measure of the neonate’s capacity to 
handle a bilirubin load.44 BBC encompasses both the albumin 
level and the nuances of albumin–bilirubin binding, which can 
be affected by several clinical conditions, including gestational 
age.44–46 Interest in the BBC has been rekindled by the develop-
ment of a point-of-care hematofluorometric device now being 
trialed in the clinical arena.46
Collectively, these observations show that much work 
remains to be done in effectively applying bilirubin mea-
surements (TSB, Bf, Bf/TSB, BBC) to identify infants at 
neurotoxicity risk. In theory, we should be able to do better 
than TSB alone, but in clinical reality, that is not yet the 
case. Finally, although Bf has biologic effects in the brain, 
the Bf level alone is not likely to dictate the risk for bilirubin 
encephalopathy. Bilirubin-induced neurotoxicity depends 
on a complex interaction between the level and duration of 
CNS Bf exposure and the innate cellular characteristics of 
the developing CNS that may predispose or protect against 
bilirubin-induced neuronal injury.9,47
Hemolysis and neurotoxicity risk
The clinical impression that hemolysis potentiates bilirubin 
neurotoxicity in neonates is long-standing and dates back to 
the early work on Rh isoimmunization and the first reports 
correlating increasing TSB and the risk for bilirubin enceph-
alopathy.48 Hemolytic conditions remain prevalent contribu-
tors to both hyperbilirubinemia and bilirubin neurotoxicity 
risk.4,49 They encompass immune-mediated hemolytic disor-
ders (Rhesus, non-Rhesus, and ABO hemolytic disease), red 
cell enzyme defects (G6PD, pyruvate kinase deficiencies), 
and red cell membrane abnormalities (hereditary spherocy-
tosis, elliptocytosis, and others), as well as some unstable 
hemoglobins.3,4,49 Although the mechanism or mechanisms 
underlying the neurotoxicity-intensifying effect is unclear, 
recent data provide strong corroboration that hemolysis aug-
ments bilirubin neurotoxicity in neonates, with Rh hemolytic 
disease and G6PD deficiency playing particularly prominent 
etiologic roles.26,33,35 More specifically, Gamaleldin et al 
showed that the TSB threshold for identifying 90% of babies 
with bilirubin encephalopathy was 25.4 mg/dL (434 µmol/L) 
in infants with neurotoxicity risk factors (primarily hemolytic 
disorders) in contrast to 31.5 mg/dL (539 µmol/L) in those 
without.33 The presence of Rh hemolytic disease alone greatly 
increased the risk for bilirubin encephalopathy (odds ratio, 
48.6; 95% confidence interval, 14–168).33
Of concern, it is increasingly apparent that the diagno-
sis of hemolysis in neonates remains problematic and, as a 
result, underrecognized. Several reports demonstrate that 
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Figure 3 Bf/TBC ratio improves prediction of bilirubin-induced brainstem response 
abnormalities.
Notes:  Receiver-operating  characteristics  of  the  total  bilirubin  concentration 
(TBC), plasma-unbound or “free” bilirubin concentration (Bf), and the Bf/TBC ratio 
as predictors of an abnormal automated auditory brainstem response are shown. 
The straight line is the expected curve (unity) if the variable has no predictive value 
(are under the curve, 0.5). The areas under the curve are Bf/TBC ratio, 0.83; Bf, 
0.69; and TBC, 0.50. The areas under the Bf/TBC and Bf are significantly greater 
than that under the TBC curve. Reprinted by permission from Macmillan Publishers 
Ltd: J Perinatol. Ahlfors Ce, Amin SB, Parker Ae. Unbound bilirubin predicts abnor-
mal  automated  auditory  brainstem  response  in  a  diverse  newborn  population. 
2009;29:305–309. Copyright © 2009.43Research and Reports in Neonatology 2014:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
187
Management of neonatal jaundice
the etiology of extreme or hazardous hyperbilirubinemia is 
often unclear and not identified,26,36,50 when almost assuredly a 
hemolytic process is an important contributor to their genesis 
in many, if not most, cases.49,51,52 Indeed, Christensen et al 
recently reported that when an exhaustive search, including 
“next-generation” sequencing of a panel of gene variants 
involved in neonatal hyperbilirubinemia, was performed, 
a specific diagnosis was made in all infants with extreme 
hyperbilirubinemia (TSB .25 mg/dL) and was explained by 
an underlying hemolytic condition in each instance.52
These data suggest that clinical indices to detect accel-
erated red blood cell turnover may be useful adjuncts in 
identifying neonates with hemolysis. The approach that has 
received the most attention in this regard is the measure-
ment of end-tidal carbon monoxide (ETCO) corrected for 
ambient CO or ETCOc.53–56 The catabolism of heme derived 
from red cell hemoglobin produces equimolar amounts of 
CO and bilirubin, providing the physiologic basis for ETCOc 
to index hemolysis.53,55,56 Previous studies have demon-
strated that elevated levels of ETCOc correlate with blood 
carboxyhemoglobin concentrations.53,55,56 Recent studies 
have detailed measurements of ETCOc levels in neonates 
and are nicely summarized in a succinct review by Tidmarsh 
and colleagues.55 Collectively, they suggest an ETCOc cutoff 
of more than 2.5 parts per million to predict the presence of 
clinically significant hemolysis.55 Although no commercial 
ETCOc device is currently available, one is in development 
and undergoing preliminary testing.55 Such an instrument 
holds potential for point-of-care application in helping 
identify neonates with hemolysis once normative data 
are first established. One can envision the measurement 
of ETCOc as an adjunct in helping to identify infants at risk 
for subsequent severe hyperbilirubinemia and in further 
stratifying treatment criteria.55,56
Identifying neonates with 
intermediate to advanced ABE
ABE defines an encephalopathic state induced by hazardous 
hyperbilirubinemia during the first days of postnatal life and 
is characterized by a constellation of abnormal clinical signs 
typically progressive in their severity. In term ($370/7 weeks’ 
gestation) and late preterm (340/7–366/7 weeks’ gestation) 
infants, the initial phase of ABE is characterized by stupor 
(lethargy), hypotonia, and poor sucking.7,10 These nonspe-
cific signs are seen in numerous clinical contexts, but in a 
hyperbilirubinemic infant, they should raise the possibility of 
early ABE. Clinical signs of intermediate to advanced stages 
of ABE are increasingly more specific to bilirubin-induced 
neurotoxicity and herald a marked increased risk for perma-
nent injury.7,10 These include hypertonia, often manifested by 
retrocollis, and opisthotonus, fever, and high-pitched cry.7,10 
Inability to feed and apnea may ensue.36.57 There is growing 
evidence that bilirubin-induced neurotoxicity resulting in 
brainstem injury may manifest clinically as symptomatic 
apneic events and presage intermediate to advanced stages 
of ABE.57 Infants younger than 34 weeks’ gestation less fre-
quently show these classic abnormal neuromotor signs.57–59 
Recurrent apnea and desaturations may be the only clinical 
manifestations of ABE in preterm infants during the neona-
tal period, if any appear at all.57–59 In contrast, CBE defines 
the permanent clinical sequelae of bilirubin toxicity that 
become evident in the first year of life and is synonymous 
with kernicterus.7,10,11
Recently, a numeric scoring system for quantifying the 
degree of ABE has been outlined; it is detailed in Table 1.36,60 
This scoring system of bilirubin-induced neurologic dysfunc-
tion may prove to be a useful clinical tool in identifying 
infants with intermediate to advanced ABE, conditions that 
pose significant risk for CBE and are an indication for the 
urgent application of bilirubin reduction strategies. Indeed, 
preliminary observations suggest this numeric approach may 
be quite reliable in characterizing the severity of ABE33,35 
and may prove helpful in managing infants with hazardous 
hyperbilirubinemia. Notably, as detailed in the section on 
exchange transfusion, the AAP recommends immediate 
exchange transfusion in any infant who is jaundiced and 
manifests signs of intermediate to advanced stages of ABE 
(hypertonia, arching, retrocollis, opisthotonos, fever, high-
pitched cry), even if the TSB is falling.11
Phototherapy
Phototherapy is the mainstay of hyperbilirubinemia treatment 
in neonates across the gestational age spectrum. In widespread 
application since the 1970s, phototherapy has resulted in a 
marked reduction in the need to perform exchange transfu-
sions to prevent hazardous hyperbilirubinemia and bilirubin 
encephalopathy.4,19,61 The effectiveness of phototherapy is 
determined by the irradiance, the surface area of exposure, 
and the light spectrum used.4,19,61
Irradiance is the radiant power, and the irradiance in a 
specific wavelength band is termed the spectral irradiance 
and is expressed as micro-Watts per centimeter squared per 
nanometer.4,19,61 There is a direct dose–response relationship 
between the efficacy of phototherapy and the irradiance used, 
and the level of irradiance is related to the distance between 
the light and the infant.4,19,61 In contrast to the early data from Research and Reports in Neonatology 2014:4 submit your manuscript | www.dovepress.com
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Tan,62 Vandborg et al recently demonstrated a linear relation-
ship between irradiance and the decrease in the TSB with no 
evidence of a saturation point.63
The surface area of the infant exposed to phototherapy 
and the spectrum of light delivered are also key elements in 
determining the efficacy of phototherapy.4,19,61 The spectrum 
of light delivered by the phototherapy unit is determined by 
the type of light source and any filters used. Unconjugated 
bilirubin absorbs light most strongly in the blue region of the 
spectrum, near 460 nm, and the penetration of tissue by light 
increases with increasing wavelength.4,19,61 Only wavelengths 
that penetrate tissue and are absorbed by bilirubin have a 
phototherapeutic effect.4,19,61 Recently, Lamola et al detailed 
the important effect hematocrit has on the efficacy of pho-
totherapy for neonatal jaundice.64,65 More specifically, they 
calculated that the wavelength at which the highest fraction 
of light is absorbed by bilirubin across a range of hematocrits 
peaked at 476 nm, not 460 nm.64 On the basis of this previ-
ously unrecognized hematocrit effect, they speculate that 
narrow-band light-emitting diode phototherapy at 476 nm 
would be 60% more effective than blue fluorescent lamps,64 a 
conclusion consistent with observations that blue-green (tur-
quoise) light with emission peak at 490 nm and bandwidth of 
65 nm is more effective than blue light.66,67 Others, however, 
have observed no difference between turquoise and blue light 
phototherapy effectiveness.68 Further study is necessary to 
clarify the potential advantage of turquoise phototherapy.
The benefit of timely phototherapy application in infants 
who show marked, potentially hazardous hyperbilirubinemia 
is clear and highlighted by the work of Mreihil et al, who 
report that configurational photoisomerization of bilirubin 
occurs almost instantaneously and is detectable in appreciable 
amounts in the blood of newborns within 15 minutes of initiat-
ing intensive phototherapy.69 These photoisomers can account 
for up to 20%–30% of the total unconjugated bilirubin and 
are less lipophilic than native bilirubin, and therefore are less 
likely to cross the blood–brain barrier.69 So the immediate 
detoxification of some bilirubin, even before it is excreted, is 
a possible additional benefit of phototherapy.4,19,61,69 Clearance 
of the structural photoisomer lumirubin is felt to be primar-
ily responsible for the ultimate bilirubin-lowering effect of 
phototherapy, although the actual contributions of individual 
isomers remain uncertain.4,19,61 Photooxidation of bilirubin is 
a slow process and a minor contributor to the elimination of 
bilirubin during phototherapy.4,19,61
The last few years have witnessed the publication of sev-
eral phototherapy treatment guidelines for premature infants 
of less than 35 weeks’ gestational age that complement 
Table 1   Clinical  bilirubin-induced  neurological  dysfunction  (BiND)  score  of  onset,  severity,  and  progression  of  acute  bilirubin 
encephalopathy, as elicited by history and physical examination
Clinical signs Bilirubin-induced  
neurological  
dysfunction score
Acute bilirubin 
encephalopathy
Mental status
  Normal 0 None
  Sleepy but able to be aroused; decreased feeding 1 Subtle
    Lethargy, poor suck, and/or irritable/jittery with strong suck 2 Moderate
  Semicoma, apnea, unable to feed, seizures, coma 3 Advanced
Muscle tone
  Normal 0 None
  Persistent mild to moderate hypotonia 1 Subtle
    Mild to moderate hypertonia alternating with hypotonia,  
beginning arching of neck and trunk on stimulation
2 Moderate
    Persistent retrocollis and opisthotonos, bicycling or  
twitching of hands and feet
3 Advanced
Cry pattern
  Normal 0 None
  High-pitched when aroused 1 Subtle
  Shrill, difficult to console 2 Moderate
  inconsolable crying or weak or absent cry 3 Advanced
Total BiND (acute bilirubin encephalopathy score)
Notes: Scores of 1–3 are consistent with subtle signs of acute bilirubin encephalopathy in infants with hyperbilirubinemia. Scores of 4–6 represent moderate acute bilirubin 
encephalopathy and are likely reversible with urgent and prompt bilirubin reduction strategies. Scores of 7–9 represent advanced acute bilirubin encephalopathy; urgent, 
prompt, and individualized intervention are recommended to prevent further brain damage, minimize severity of sequelae, and possibly reverse acute damage. Reprinted by 
permission from Macmillan Publishers Ltd: J Perinatol. Johnson L, Bhutani vK, Karp K, Sivieri eM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 
to 2004). 2009;29(Suppl 1):S25–S45. Copyright © 2009.36Research and Reports in Neonatology 2014:4 submit your manuscript | www.dovepress.com
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those previously published for 35 weeks’ gestation and older 
newborns.11,58 As there are limited data for evidence-based 
recommendations in preterm neonates, these guidelines 
are, of necessity, consensus-based and provided by differ-
ent experts, none of whom would make any claim for the 
greater validity of one approach over another.58,70
One subgroup of preterm neonates treated with photo-
therapy has recently been carefully studied, and this work 
merits specific comment. The Neonatal Research Network 
performed a prospective randomized controlled trial in 
extremely low birth weight (,1,000 g) infants of aggressive 
phototherapy (used prophylactically and started at 23±9 hours 
after birth) versus conservative phototherapy (started when 
the TSB level was $8 mg/dL [137 µmol/L] for infants 500–
750 g, or $10 mg/dL [171 µmol/L] for infants 751–1,000 
g).71 There was no difference in the primary outcome of 
death or neurodevelopmental impairment at 18–20 months 
of corrected age, but among survivors, when compared with 
conservative phototherapy, aggressive phototherapy produced 
a significant decrease in neurodevelopmental impairment, 
hearing loss, profound impairment, and athetosis.71
An unexpected finding in this study was a 5% increase 
in mortality in infants with birth weights 501–750 g who 
received aggressive phototherapy (relative risk, 1.05; 95% 
confidence interval, 0.90–1.22]).71–73 The difference was not 
statistically significant, but a post hoc, Bayesian analysis 
estimated an 89% probability that aggressive phototherapy 
increased the rate of deaths in this subgroup.71–73 In an earlier 
Eunice Kennedy Shriver National Institute of Child Health 
and Human Development study, infants with birth weights 
of 1,000 g or less who received phototherapy had a 19% 
increase in mortality compared with control infants (no 
phototherapy; P=0.14).58,74 The reasons for these findings are 
not clear, but these tiny, immature infants have gelatinous, 
thin skin, through which light will penetrate readily, reaching 
more deeply into the subcutaneous tissue.58 There is some 
evidence that phototherapy can produce oxidative injury 
to cell membranes, and such injury could have an adverse 
effect on these immature infants.58 In the Neonatal Research 
Network study, the average irradiance level was reported 
as 22–23 µw/cm2/nm, and the “target irradiance level” was 
15–40 µw/cm2/nm.71
Because of the reported increase in mortality in infants 
with birth weights 501–750 g, it has been recommended 
that phototherapy be initiated at lower irradiance levels in 
extremely low birth weight neonates and that these levels 
are only increased, or the surface area of the infant exposed 
to phototherapy is increased, if the TSB continues to rise.58 
One caveat to this approach is that the irradiance in the earlier 
Eunice Kennedy Shriver National Institute of Child Health 
and Human Development study from the 1970s was presum-
ably low.73–75 As a result, intermittent or cycled, as opposed 
to continuous, phototherapy is being given consideration as 
a potential alternative treatment strategy in the extremely 
low birth weight neonate.73,75
exchange transfusion
Exchange transfusion remains an important, if infrequently 
required, clinical intervention to prevent or reduce the risk for 
kernicterus.4,19,20 The prevention of Rh (D) hemolytic disease 
with Rh (D) immunoglobulin and the more effective use of 
intensive phototherapy have led to a dramatic decline in the 
number of exchange transfusions performed.4,19 Although 
there is little new to report on exchange transfusion per se, 
it is important to highlight a few clinical issues that remain 
relevant to its effective use.
To what hematocrit should the donor blood  
be reconstituted for exchange transfusion?
Given that bilirubin is bound to albumin in the vascular 
compartment, the efficacy of a double-volume exchange 
transfusion is a function of the plasma volume, and most 
important, the mass of albumin exchanged.76,77 It follows 
that donor blood of high plasma volume, that is, low 
hematocrit (∼40%), to enhance the amount of bilirubin-
free albumin introduced into the infant’s circulation during 
exchange is preferred.76–78 Surprisingly, this fundamental 
aspect of performing an exchange transfusion is not 
consistently highlighted in current reviews or textbook 
recommendations.
exchange transfusion in intermediate  
to advanced stages of ABe
The 2004 AAP statement on hyperbilirubinemia specifies 
that “immediate exchange transfusion is recommended in 
any infant who is jaundiced and manifests signs of interme-
diate to advanced stages of acute bilirubin encephalopathy 
(hypertonia, arching, retrocollis, opisthotonos, fever, high-
pitched cry) even if the TSB is falling.”11 This recommenda-
tion is consistent with reports79,80 that at least some infants 
so treated may escape unscathed without chronic bilirubin 
encephalopathy (kernicterus) and with earlier observations 
that a decline in TSB coincident with the clinical onset of 
intermediate to advanced signs of ABE can occur and is often 
a prognostic sign for poor outcome, as opposed to a sign of 
clinical improvement.81Research and Reports in Neonatology 2014:4 submit your manuscript | www.dovepress.com
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Should emergency release uncross-matched blood 
be used in exchange transfusion for advanced ABe?
Given the urgency of an exchange transfusion in an infant 
with intermediate to advanced stages of ABE, it has been 
suggested that emergency release uncross-matched blood 
be used.82 This recommendation merits specific comment. 
First, emergency release blood is in the form of packed red 
blood cells with a hematocrit that approximates 70%–75%, 
and therefore could not be used immediately in an exchange 
transfusion because of polycythemia and hyperviscosity. The 
unit would need to be reconstituted in type AB fresh frozen 
plasma to an appropriate hematocrit (target, 35%–40%) to 
be both safe and effective. The time required to thaw the 
fresh frozen plasma and reconstitute the packed red blood 
cells would approximate 1.5–2.0 hours, which is more than 
sufficient time for the blood bank to identify and cross-
match a compatible unit that could then be reconstituted 
with the thawed AB fresh frozen plasma. Emergency units 
are typically cytomegalovirus safe, leukoreduced, and stored 
in citrate-phosphate-dextrose less than 7 days old instead 
of adenosine, dextrose, saline, mannitol (Adsol; Baxter, 
Deerfield, IL, USA), and so would not require washing. 
Although blood for double-volume exchange would need to 
be irradiated, this could be accomplished in about 5 minutes 
with an irradiator on site. However, it is quite important to use 
mother’s serum or cord blood to perform a cross-match when 
red cell alloantibodies are the cause, or possible cause, of 
hazardous hyperbilirubinemia, as this ensures compatibility 
of the chosen unit. When the cause of hazardous hyperbiliru-
binemia and advanced bilirubin encephalopathy is known to 
be unrelated to red cell antibodies, then there is no significant 
advantage to using cross-matched blood, but there would be 
little to no time savings in using an uncross-matched unit, 
given these processing requirements. It is notable in this 
regard that in Hansen’s report on the reversibility of acute 
intermediate phase bilirubin encephalopathy,80 the interval 
between hospital admission and initiation of double-volume 
exchange transfusion was between 3.5 and 9 hours, with 
a mean of 6.5 hours (TWR Hansen, Rikshospitalet, Oslo, 
Norway, personal communication, January, 2013).
Pharmacologic treatment
intravenous immunoglobulin
Early studies4,19 and a systematic review83 suggested that the 
administration of intravenous immunoglobulin (IVIG) to 
infants with Rh hemolytic disease would significantly reduce 
the need for exchange transfusion. Two recent   randomized 
controlled trials, however, showed no benefit from the admin-
istration of IVIG to newborns with Rh hemolytic disease,84,85 
and a Cochrane meta-analysis86 concluded that the efficacy of 
IVIG was not conclusive in Rh or ABO hemolytic disease of 
the newborn. The mechanism of action of IVIG is unknown, 
but it is possible that it might alter the course of immune-
mediated hemolytic disease by blocking Fc receptors, thereby 
inhibiting hemolysis.4,19 The 2004 AAP guideline reserves the 
use of IVIG to direct Coombs-positive infants whose TSB 
continues to rise despite intensive phototherapy or whose 
TSB is within 2–3 mg/dL of the exchange level.11
Heme oxygenase inhibitors
The rate-limiting step in bilirubin production is the conver-
sion of heme to biliverdin by heme oxygenase.4,19,87 Certain 
synthetic metalloporphyrins are powerful competitive inhibi-
tors of heme oxygenase and suppress the formation of biliru-
bin.4,19,87 One such compound that has been studied extensively 
is tin mesoporphyrin (SnMP).4,19,87 A series of controlled clini-
cal trials have demonstrated that SnMP is a potent inhibitor 
of heme oxygenase and is highly effective in reducing TSB 
levels and the requirements for phototherapy in term and 
preterm neonates.4,19 The only reported adverse effect has 
been a transient erythema that disappeared without sequelae 
in infants who received white light phototherapy after SnMP 
administration.4,19 This drug is still awaiting approval by the 
US Food and Drug Administration, although it can be obtained 
for compassionate use (InfaCare Pharmaceutical Corp, Tre-
vose, PA, USA).4 If approved, SnMP could find immediate 
application in preventing the need for exchange transfusion 
in infants who are not responding to phototherapy.4,19 Other 
metalloporphyrin formulations are currently under study that 
hold the additional promise of being orally bioavailable and 
nonphotosensitizing.87,88 A concise current review of ongoing 
research efforts to optimize metalloporphyrin effectiveness 
and safety profile is provided by Schulz et al.87
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